The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Alumis Inc | Common Stock | 022307102 | 8,687,893 | 653,225 | SH | SOLE | 653,225 | 0 | 0 | ||
enGene Holdings Inc. | Common Stock | 29286M105 | 10,150,047 | 1,076,357 | SH | SOLE | 1,076,357 | 0 | 0 | ||
enGene Holdings Inc. | Warrant | 29286M113 | 382,587 | 321,502 | SH | SOLE | 321,502 | 0 | 0 | ||
Ikena Oncology | Common Stock | 45175G108 | 3,711,053 | 2,249,123 | SH | SOLE | 2,249,123 | 0 | 0 | ||
Immunic Inc | Common Stock | 4525EP101 | 1,984,858 | 1,788,160 | SH | SOLE | 1,788,160 | 0 | 0 | ||
Lexeo Therapeutics | Common Stock | 52886X107 | 37,788,700 | 2,355,904 | SH | SOLE | 2,355,904 | 0 | 0 | ||
Morphic Holding | Common Stock | 61775R105 | 5,445,953 | 159,846 | SH | SOLE | 159,846 | 0 | 0 | ||
Nuvation Bio | Common Stock Class A | 67080N101 | 38,765,581 | 13,275,884 | SH | SOLE | 13,275,884 | 0 | 0 | ||
Replimune Group | Common Stock | 76029N106 | 22,151,871 | 2,461,319 | SH | SOLE | 2,461,319 | 0 | 0 | ||
Sana Biotechnology, Inc. | Common Stock | 799566104 | 4,606,875 | 843,750 | SH | SOLE | 843,750 | 0 | 0 | ||
Syros Pharmaceuticals | Common Stock | 87184Q206 | 1,296,553 | 251,270 | SH | SOLE | 251,270 | 0 | 0 |